Immunomodulatory therapy for sepsis: An update
Opal, Steven M.
SourceExpert Review of Anti-Infective Therapy
Google Scholar check
MetadataShow full item record
Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality. As the pathophysiologic events that take place during sepsis are being elucidated, new molecules that target each step of those pathways are being tested. However, a lot of those molecules affect various mediators of the sepsis cascade including inflammatory cytokines, cellular receptors, nuclear transcription factors, coagulation activators and apoptosis regulators. Over the last decade, a multitude of clinical trials and animal studies have investigated strategies that aimed to restore immune homeostasis either by reducing inflammation or by stimulating the innate and adaptive immune responses. Antibiotics, statins and other molecules with multipotent immunomodulatory actions have also been studied in the treatment of sepsis. © 2011 Expert Reviews Ltd.
Showing items related by title, author, creator and subject.
Caspase-independent pathways of programmed cell death: The unraveling of new targets of cancer therapy? Constantinou, Constantina; Papas, Konstantinos A.; Constantinou, Andreas I. (2009)In the past few years, accumulating evidence in the literature supports the existence of pathways of caspase-independent programmed cell death (CI-PCD). These pathways are likely to be acting as 'death backup systems' that ...
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Cutsem, E. Van; Dicato, M.; Arber, N.; Berlin, J.; Cervantes, A.; Ciardiello, F.; Gramont, A. De; Diaz-Rubio, E.; Ducreux, M.; Geva, R.; Glimelius, B.; Glynne-Jones, R.; Grothey, Axel; Gruenberger, T.; Haller, D.; Haustermans, K.; Labianca, R.; Lenz, H. J.; Minsky, B.; Nordlinger, B.; Ohtsu, A.; Pavlidis, Nicholas; Rougier, P.; Schmiegel, W.; Velde, C. Van de; Schmoll, H. J.; Sobrero, A.; Tabernero, Josep (2010)The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy ...
Selective activation of TNFR1 and NF-ΚB inhibition by a novel biyouyanagin analogue promotes apoptosis in acute leukemia cells Savva, Christiana G.; Totokotsopoulos, S.; Nicolaou, K. C.; Neophytou, Christiana M.; Constantinou, Andreas I. (2016)Background: Acquired resistance towards apoptosis is a hallmark of cancer. Elimination of cells bearing activated oncogenes or stimulation of tumor suppressor mediators may provide a selection pressure to overcome resistance. ...